Scientific Program
The Group’s scientific program includes all phases of clinical research (phases 1 to 4). It also covers all types and subtypes of breast cancer: Hormone-receptor-positive – estrogen or progesterone (HR +); HER2 protein overexpression (HER2 +); Triple-negative, which does not involve hormone receptors nor those of the HER2 protein (HR- / HER2-); Genetic mutation (somatic / spontaneous or hereditary / transmitted), as well as all stages of the disease or extent of cancer, from in situ and early stages to metastatic cancer.
| Cancer Subtype | Time of treatment | Treatment Types |
|---|---|---|
| HR+/HER2- | Neoadjuvant | Chemotherapy |
| HR-/HER2+ | Adjuvant | Hormonal therapy |
| HR-/HER2- (mutated or not) | Post-Neoadjuvant | Immunotherapy |
| HR+/HER2+ | Prevention | |
| Genetic Mutations | Radiation therapy | |
| Supportive therapy | ||
| Surgery | ||
| Targeted therapy |
Clinical Trials Performed Within the Group
The consortium is presently involved in 15 or so clinical trials and is considering new ones regularly. Please refer to the table below to see what trials are ongoing at the Group’s hospitals.
Update in the context of COVID-19:
At the request of the Ministère de la Santé et des Services Sociaux du Québec, research activities in adult cancerology have generally ceased, except for treatments already started and for patients for whom there is no other therapeutic alternative or those for whom a clinical benefit has been evaluated by their doctor. However, we are working proactively and in close collaboration with several groups to facilitate resumption of research activities as quickly as the health crisis permits.
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+ & HER2- | TROPICS-02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02) | Immunomedics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS | In preparation |
| HR+ & HER2- | NSABP-B58 / MonarchE Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | Eli Lilly in collaboration with NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR+ & HER2- | NeaOnQ A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec | CHUM in collaboration with Genomic Health | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In recruitment |
| HR+ & HER2- | CONTESSA (ODO-TE-B301) Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane | Odonate Therapeutics, Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | EMERALD (RAD1901-308) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD) | Radius Pharmaceuticals, Inc. | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In preparation |
| ER+ & HER2- | CheckMate 7A8 (CA209-7A8) Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In preparation |
| ER+ & HER2- | CheckMate 7FL (CA209-7FL) Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL | In preparation |
| ER+ & HER2- | KEYNOTE-756 Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer | Merck Sharp & Dohme Corp. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| ER+ & HER2- | NSABP-FB13 Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer | NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR+ & HER2- | NATALEE (TRIO033) Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer | Novartis Pharmaceuticals in collaboration with Translational Research in Oncology | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HR+ & HER2- | XENERA Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease | Boehringer Ingelheim | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HER2- & BRCA1/2 | LUCY Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations | Astra Zeneca in collaboration with Parexel | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR- & HER2- (Triple negative) | NSABP-B59 Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | NSABP Foundation Inc in collaboration with Genentech Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (CUSM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR- & HER2- (Triple negative) | ATTAIN Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | Nektar Therapeutics | MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- / ER- & HER2- / HER2+ | TRIO-030 Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20 | Translational Research in Oncology (TRIO) | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | CONTESSA 2 Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane | Odonate Therapeutics Inc. | ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HR- & HER2- (Triple negative) / HER2- | CONTESSA-TRIO Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC | Odonate Therapeutics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE | In recruitment |
| Cancer Subtype | Study Name | Sponsor | Participating Hospitals | Status |
|---|---|---|---|---|
| HR+ & HER2- | TROPICS-02 (IMMU132-09) Phase 3 Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens (TROPICS-02) | Immunomedics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS | In preparation |
| HR+ & HER2- | NSABP-B58 / MonarchE Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer | Eli Lilly in collaboration with NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR+ & HER2- | NeaOnQ A prospective clinical utility and economic impact study of the Oncotype DX® Recurrence Score in in node-positive patients and in candidates for neoadjuvant therapy in Quebec | CHUM in collaboration with Genomic Health | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In recruitment |
| HR+ & HER2- | CONTESSA (ODO-TE-B301) Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane | Odonate Therapeutics, Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| ER+ & HER2- | EMERALD (RAD1901-308) Elacestrant Monotherapy vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer Following CDK4/6 Inhibitor Therapy: A Phase 3 Randomized, Open-label, Active-controlled, Multicenter Trial (EMERALD) | Radius Pharmaceuticals, Inc. | CHU DE QUEBEC – UNIVERSITE LAVAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) MCGILL UNIVERSITY HEALTH CENTER (MUHC) | In preparation |
| ER+ & HER2- | CheckMate 7A8 (CA209-7A8) Randomized, Non-comparative Neoadjuvant Phase II Study in Patients With ER+/HER2- Breast Cancer >= 2 cm With Safety Run-in, Assessing Nivolumab + Abemaciclib or Palbociclib + Anastrozole (CheckMate 7A8) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In preparation |
| ER+ & HER2- | CheckMate 7FL (CA209-7FL) Randomized, Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Patients With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | Bristol-Myers Squibb | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'ESTRIE – CHUS CIUSSS DE L’OUEST-DE-L’ÎLE-DE-MONTRÉAL/ ST. MARY'S HOSPITAL | In preparation |
| ER+ & HER2- | KEYNOTE-756 Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Breast Cancer | Merck Sharp & Dohme Corp. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL / JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| ER+ & HER2- | NSABP-FB13 Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer | NSABP Foundation Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR+ & HER2- | NATALEE (TRIO033) Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer | Novartis Pharmaceuticals in collaboration with Translational Research in Oncology | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HR+ & HER2- | XENERA Multi-center, double-blind, placebo-controlled, randomised phase II trial to compare the efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women in post-menopausal women with Hormone Receptor Positive (HR+) and HER2- negative metastatic breast cancer and non-visceral disease | Boehringer Ingelheim | MCGILL UNIVERSITY HEALTH CENTER (MUHC) CHU DE QUEBEC – UNIVERSITE LAVAL | In recruitment |
| HER2- & BRCA1/2 | LUCY Lynparza Breast Cancer Real-World Utility, Clinical Effectiveness and Safety Study - A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Monotherapy in the Treatment of HER2-ve Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutations | Astra Zeneca in collaboration with Parexel | CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL | Closed to recruitment |
| HR- & HER2- (Triple negative) | NSABP-B59 Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo | NSABP Foundation Inc in collaboration with Genentech Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (CUSM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | In recruitment |
| HR- & HER2- (Triple negative) | ATTAIN Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine | Nektar Therapeutics | MCGILL UNIVERSITY HEALTH CENTER (MUHC) | Closed to recruitment |
| HR+ & HER2- / ER- & HER2- / HER2+ | TRIO-030 Pre-surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist ODM-20 | Translational Research in Oncology (TRIO) | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CHU DE QUEBEC – UNIVERSITE LAVAL CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT | Closed to recruitment |
| HR+ & HER2- | CONTESSA 2 Multinational, Multicenter, Phase 2 Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane | Odonate Therapeutics Inc. | ENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL CHU DE QUEBEC – UNIVERSITE LAVAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CHUS | In recruitment |
| HR- & HER2- (Triple negative) / HER2- | CONTESSA-TRIO Multicenter, Phase 2 Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC | Odonate Therapeutics Inc. | CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL (CHUM) CIUSSS DE L'EST-DE-L'ILE-DE-MONTREAL/ HOPITAL MAISONNEUVE-ROSEMONT CIUSSS DU CENTRE-OUEST-DE-L'ILE-DE-MONTREAL/ JEWISH GENERAL HOSPITAL MCGILL UNIVERSITY HEALTH CENTER (MUHC) CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE | In recruitment |